Study 55 of 60Semaglutide literaturebiorxiv-preprint · Observational2026

Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study

Lower doses of compounded semaglutide may achieve significant weight loss when combined with behavioral programs, reaching 91% of the weight loss seen with higher doses in 16 weeks.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the semaglutide corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

This study evaluated the efficacy of a lower dose of compounded semaglutide in conjunction with a behavioral weight management program over 16 weeks. Participants included users of Noom Weight, Noom Microdose GLP-1 Rx Program, and Noom GLP-1 Rx Program. Weight loss results showed NMGP users lost 8.3% and NGP users lost 8.6% of their baseline weight.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

At 16 weeks, NMGP users lost 8.3% of their baseline weight.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Objective This 16-week, real-world retrospective cohort study of a behavioral weight management program evaluated the efficacy of a lower dose of compounded semaglutide on weight loss. Methods Weight loss was compared among Noom Weight (NW) users, Noom Microdose GLP-1 Rx Program (NMGP) users prescribed a low dose of compounded semaglutide (up to 0.6mg/weekly), and Noom GLP-1 Rx Program (NGP) users prescribed a dose up to 1.2mg/weekly of compounded semaglutide via multiple-group latent growth curve models for the full sample and propensity score matched cohort. Users were matched on demographic characteristics, Area Deprivation Index, baseline Body Mass Index, and urbanicity. Results In the full sample, participants (N = 29,788) were mostly middle-aged, urban-dwelling females. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 8.6% of their baseline weight (all comparisons p ≤ .001). In the matched cohort (N = 3,657; n= 1,219 per group), participant characteristics were similar. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 9.1% of their initial weight (all comparisons p < .001). Conclusions This large, retrospective cohort reports lower doses of compounded semaglutide alongside a behavioral companion achieve 91% of the weight loss of a higher dose of compounded semaglutide in the first 16 weeks.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Semaglutide corpus

DGLP-1s and criminality: US trial will test whether semaglutide can fight crime.BMJ (Clinical research ed.) · 2026—DThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.review BCardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Journal of diabetes and metabolic disorders · 2026 · n=271685 · 4.6% primary composite outcome incidence in tirzepatide group vs. 5.5% in semaglutide group, ARD -0.9%, 95% CI -1.01 to -0.77, HR 0.9, 95% CI 0.92─0.96.Human BWeight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.Clinical obesity · 2023 · 30% TWL and 12 kg/m² BMI reduction for SG at 12 months, p < 0.001.Human DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · 2026 · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.review BSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 2026 · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.Human